Dr Nooka reviews the patient reported outcomes from the MajesTEC-1 trial in patients with relapsed/refractory multiple myeloma.
Martin TG, Moreau P, Usmani SZ et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1. Abstract presented at: 2022 American Society of Clinical Oncology, June 3-7, 2022; Chicago, IL & Virtual. Abstract # 8033.